Discussion Forums > Working Towards a Cure

Bluebird Bio Releases Data on Current Gene Therapy Trials

<< < (29/39) > >>

Canadian_Family:
bluebird bio Inc Opens Phase 3 Study of LentiGlobin™ Drug Product in Patients with Transfusion-Dependent Beta-Thalassemia

http://www.smarteranalyst.com/2016/09/08/company-update-nasdaqblue-bluebird-bio-inc-opens-phase-3-study-lentiglobin-drug-product-patients-transfusion-dependent-beta-thalassemia/

Parin:
Thank you Canadian_Family for sharing...Its good news for all patients and parents.

Andy Battaglia:

--- Quote ---In this study, the process by which the patient’s cells are transduced with LentiGlobin will be modified by the addition of two additives during the transduction step of the manufacturing process, intended to increase vector copy number and the percentage of cells successfully transduced.
--- End quote ---

I know some get discouraged quickly over early results in some patients, but this process continues to be refined and improved. My understanding is that the doctors running the trials are very optimistic about the eventual outcome, including that for beta zero patients. Patience is needed.

Parin:
Andy,

Can you please explain this more..i didnt get that. "addition of two additives during the transduction"

Andy Battaglia:
The hoped for result of these new additives to the process is "intended to increase vector copy number and the percentage of cells successfully transduced" What this means is that more beta globin should be produced with these changes, which would lead to a greater increase in Hb. Even though this particular study is for non beta zero patients, these changes should mean that the process will also mean a higher increase in Hb in beta zero patients.

Navigation

[0] Message Index

[#] Next page

[*] Previous page